Lutathera is the brand name for lutetium Lu 177 dotatate, a radiolabeled somatostatin analogue used in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. It is administered as an injection and has FDA approvals in adult and pediatric populations. The first FDA approval was on January 26, 2018.
The radioligand therapeutics market in cancer treatment is estimated to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at a 13.1% CAGR. Growth is supported by approved products Pluvicto and Lutathera and expanding use of PSMA and SSTR-targeted therapies.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.
Novartis announced plans to establish a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion US expansion. The facility is expected to be operational in 2028.
Radiopharmaceuticals are emerging as a promising therapeutic class in oncology, with theranostic approaches combining diagnostics and treatment gaining particular attention. Major pharmaceutical companies have invested billions in acquisitions while venture financing reached record levels.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05987176 |
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases |
TERMINATED | PHASE2 |
| NCT05513469 |
Biomarker Identification of Radionuclide Therapy-induced Radiation Responses |
UNKNOWN | NA |
| NCT04954820 |
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET |
RECRUITING | PHASE2 |
| NCT04614766 |
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors |
WITHDRAWN | PHASE1/PHASE2 |
| NCT04609592 |
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery |
RECRUITING | PHASE1 |
| NCT04039516 |
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy |
UNKNOWN | PHASE2 |
| NCT03972488 |
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03971461 |
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03691064 |
Post-Authorization Long-Term Safety Study of LUTATHERA |
ACTIVE_NOT_RECRUITING |
